Reports Q3 revenue $37.9M. consensus $42.96M. The company said, “We have two compelling businesses in MRD and Immune Medicine, which continue to make significant progress in divergent ways. Given the advancements achieved to date by each business and their respective investment needs, we are conducting a review of strategic alternatives to maximize value for our patients and shareholders.” It added that a strategic review underway with Goldman Sachs to maximize the value of the MRD and Immune Medicine businesses. Its cash, cash equivalents and marketable securities was $371.1M as of September 30.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADPT:
- Adaptive Biotechnologies announces new collaboration with BeiGene
- Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
- Adaptive Biotechnologies price target lowered to $10 from $13 at Morgan Stanley
- Adaptive Biotechnologies price target lowered to $13 from $14 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today